Lithium treatment arrests the development of neurofibrillary tangles in mutant tau transgenic mice with advanced neurofibrillary pathology

Journal of Alzheimer's Disease

Volumn 19, Issue 2, 2010, Pages 705-719

  Leroy, Karelle ^a   Ando, Kunie ^a   Héraud, Céline ^a   Yilmaz, Zehra ^a   Authelet, Michèle ^a   Boeynaems, Jean Marie ^b   Buée, Luc ^c   De Decker, Robert ^a   Brion, Jean Pierre ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b ERASME HOSPITAL   (Belgium)

^c JEAN PIERRE AUBERT RESEARCH CENTER   (France)

Author keywords

Lithium; Neurofibrillary tangles; Phosphorylation; Tau; Transgenic mouse; Treatment

Indexed keywords

BETA CATENIN; GLYCOGEN SYNTHASE KINASE 3BETA; LITHIUM CARBONATE; MUTANT PROTEIN; SODIUM CARBONATE; TAU PROTEIN;

AGED; AMNESIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; DEGENERATIVE DISEASE; DIURESIS; DRUG BLOOD LEVEL; DRUG EFFICACY; ENZYME INHIBITION; ENZYME STABILITY; FEEDING; FLUID INTAKE; HIPPOCAMPUS; IMMUNOPRECIPITATION; MOTOR DYSFUNCTION; MOUSE; NEPHROGENIC DIABETES INSIPIDUS; NEPHROTOXICITY; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NEUROPATHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; SCIATIC NERVE; SPINAL CORD; TRANSGENIC MOUSE; UBIQUITINATION; WORKING MEMORY;

EID: 77049116286     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-1276     Document Type: Article

References (61)

1. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 82, 239-259.
2. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42, 631-639.
3. Mazanetz MP, Fischer PM (2007) Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat Rev Drug Discov 6, 464-479.
4. Hanger DP, Anderton BH, Noble W (2009) Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med 15, 112-119.
5. Ballatore C, Lee VMY, Trojanowski JQ (2007) Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 8, 663-672.
6. Leroy K, Brion JP (1999) Developmental expression and localization of glygogen synthase-kinase 3b in rat brain. J Chem Neuroanat 16, 279-293.
7. Pei JJ, Braak E, Braak H, Grundke-Iqbal I, Iqbal K,WinbladB, Cowburn RF (1999) Distribution of active glycogen synthase kinase 3β (GSK-3β) in brains staged for Alzheimer disease neurofibrillary changes. J Neuropathol Exp Neurol 58, 1010-1019.
8. Leroy K, Yilmaz Z, Brion JP (2007) Increased level of active GSK-3β in Alzheimer's disease and accumulation in argyrophilic grains and in neurons at different stages of neurofibrillary degeneration. Neuropathol Appl Neurobiol 33, 43-55.
9. Hernandez F, Avila J (2008) The role of glycogen synthase kinase 3 in the early stages of Alzheimer's disease. FEBS Lett 582, 3848-3854.
10. Hooper C, Killick R, Lovestone S (2008) The GSK3 hypothesis of Alzheimer's disease. J Neurochem 104, 1433-1439.
11. Klein PS, Melton DA (1996) A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A 93, 8455-8459.
12. Stambolic V, Ruel L, Woodgett JR (1996) Lithium inhibits glycogen synthase kinase-3 activity and mimicsWingless signalling in intact cells. Curr Biol 6, 1664-1668.
13. Hong M, Chen DCR, Klein PS, Lee VMY (1997) Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. J Biol Chem 272, 25326-25332.
14. Muñoz-Montaño JR, Moreno FJ, Avila J, D́iaz-Nido J (1997) Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons. FEBS Lett 411, 183-188.
15. Lovestone S, Davis DR, Webster MT, Kaech S, Brion JP, Matus A, Anderton BH (1999) Lithium reduces tau phosphorylation. Effects in living cells and in neurons at therapeutic concentrations. Biol Psychiatry 45, 995-1003.
16. Mudher A, Shepherd D, Newman TA, Mildren P, Jukes JP, Squire A, Mears A, Berg S, MacKay D, Asuni AA, Bhat R, Lovestone S (2004) GSK-3 beta inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila. Mol Psychiatry 9, 522-530.
17. Hooper C, Markevich V, Plattner F, Killick R, Schofield E, Engel T, Hernandez F, Anderton B, Rosenblum K, Bliss T, Cooke SF, Avila J, Lucas JJ, Giese KP, Stephenson J, Lovestone S (2007) Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. Eur J Neurosci 25, 81-86.
18. Phiel CJ,Wilson CA, LeeVMY, Klein PS (2003) GSK-3αregulates production of Alzheimer's disease amyloid-β peptides. Nature 423, 435-439.
19. Nakashima H, Ishihara T, Suguimoto P, Yokota O, Oshima E, Kugo A, Terada S, Hamamura T, Trojanowski JQ, Lee VMY, Kuroda S (2005) Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies. Acta Neuropathol (Berl) 110, 547-556.
20. Perez M, Hernandez F, Lim F, Diaz-Nido J, Avila J (2003) Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J Alzheimers Dis 5, 301-308.
21. Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F, Gaynor K, Wang L, LaFrancois J, Feinstein B, Burns M, Krishnamurthy P, Wen Y, Bhat R, Lewis J, Dickson D, Duff K (2005) Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci U S A 102, 6990-6995.
22. Caccamo A, Oddo S, Tran LX, LaFerla FM (2007) Lithium reduces tau phosphorylation but notAbeta orworking memory deficits in a transgenic model with both plaques and tangles. Am J Pathol 170, 1669-1675.
23. Engel T, Goni-Oliver P, Lucas JJ, Avila J, Hernandez F (2006) Chronic lithium administration to FTDP-17 tau and GSK-3 beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J Neurochem 99, 1445-1455.
24. Leroy K, Bretteville A, Schindowski K, Gilissen E, Authelet M, De Decker R, Yilmaz Z, Buee L, Brion JP (2007) Early axonopathy preceding neurofibrillary tangles in mutant tau transgenic mice. Am J Pathol 171, 976-992.
25. Schindowski K, Bretteville A, Leroy K, Begard S, Brion JP, Hamdane M, Buee L (2006) Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am J Pathol 169, 599-616.
26. Thompson JC (2003) Development of an automated photometric assay for serum lithium and use of binding equilibrium expressions to optimize results. Clin Chim Acta 327, 149-156.
27. Lalonde R (2002) The neurobiological basis of spontaneous alternation. Neurosci Biobehav Rev 26, 91-104.
28. Holcomb LA, Gordon MN, Jantzen P, Hsiao K, Duff K, Morgan D (1999) Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: Lack of association with amyloid deposits. Behav Genet 29, 177-185.
29. Brion JP, Hanger DP, Bruce MT, Couck AM, Flament-Durand J, Anderton BH (1991) Tau in Alzheimer neurofibrillary tangles: N-and C-terminal regions are differentially associated with paired helical filaments and the location of a putative abnormal phosphorylation site. Biochem J 273, 127-133.
30. Goedert M, Jakes R, Vanmechelen E (1995) Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205. Neurosci Lett 189, 167-170.
31. Goedert M, Jakes R, Crowther RA, Cohen P, Vanmechelen E, Vandermeeren M, Cras P (1994) Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: Identification of phosphorylation sites in tau protein. Biochem J 301, 871-877.
32. Otvos L, Jr., Feiner L, Lang E, Szendrei GI, Goedert M, Lee VM-Y (1994) Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J Neurosci Res 39, 669-673.
33. Biernat J, Mandelkow E-M, Schröter C, Lichtenberg-Kraag B, Steiner B, Berling B, Meyer H, Mercken M, Vandermeeren A, Goedert M, Mandelkow E (1992) The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine-proline motifs upstream of the microtubule binding region. EMBO J 11, 1593-1597.
34. Brion JP, Hanger DP, Couck AM, Anderton BH (1991) A68 proteins in Alzheimer's disease are composed of several tau isoforms in a phosphorylated state which affects their electrophoretic mobilities. Biochem J 279, 831-836.
35. Oksche A, RosenthalW(1998) The molecular basis of nephrogenic diabetes insipidus. J Mol Med 76, 326-337.
36. Chalecka-Franaszek E, Chuang DM (1999) Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamateinduced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci U S A 96, 8745-8750.
37. Sarkar S, Floto RA, Berger Z, Imarisio S, Cordenier A, Pasco M, Cook LJ, Rubinsztein DC (2005) Lithium induces autophagy by inhibiting inositol monophosphatase. J Cell Biol 170, 1101-1111.
38. Petrucelli L, Dickson D, Kehoe K, Taylor J, Snyder H, Grover A, De Lucia M, McGowan E, Lewis J, Prihar G, Kim J, Dillmann WH, Browne SE, Hall A, Voellmy R, Tsuboi Y, Dawson TM, Wolozin B, Hardy J, Hutton M (2004) CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum Mol Genet 13, 703-714.
39. Shimura H, Schwartz D, Gygi SP, Kosik KS (2004) CHIPHsc70 complex ubiquitinates phosphorylated tau and enhances cell survival. J Biol Chem 279, 4869-4876.
40. Braak E, Braak H, Mandelkow E-M (1994) A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads. Acta Neuropathol (Berl) 87, 554-567.
41. Alonso AD, Zaidi T, Novak M, Grundke-Iqbal I, Iqbal K (2001) Hyperphosphorylation induces self-assembly of t into tangles of paired helical filaments/straight filaments. Proc Natl Acad Sci U S A 98, 6923-6928.
42. Godemann R, Biernat J, Mandelkow E, Mandelkow EM (1999) Phosphorylation of tau protein by recombinant GSK-3b: pronounced phosphorylation at select Ser/Thr-Pro motifs but no phosphorylation at Ser262 in the repeat domain. FEBS Lett 454, 157-164.
43. De Sarno P, Li XH, Jope RS (2002) Regulation of Akt and glycogen synthase kinase-3b phosphorylation by sodium valproate and lithium. Neuropharmacology 43, 1158-1164.
44. Ryves WJ, Harwood AJ (2001) Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem Biophys Res Commun 280, 720-725.
45. Ding VW, Chen RH, McCormick F (2000) Differential regulation of glycogen synthase kinase 3beta by insulin and Wnt signaling. J Biol Chem 275, 32475-32481.
46. Doble BW,Woodgett JR (2003) GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 116, 1175-1186.
47. Peifer M, Polakis P (2000) Cancer-Wnt signaling in oncogenesis and embryogenesis-a look outside the nucleus. Science 287, 1606-1609.
48. Gould TD, Chen G, Manji HK (2004) In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacology 29, 32-38.
49. Staal FJ, Noort Mv M, Strous GJ, Clevers HC (2002) Wnt signals are transmitted through N-terminally dephosphorylated beta-catenin. EMBO Rep 3, 63-68.
50. Davies SP, Reddy H, Caivano M, Cohen P (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351, 95-105.
51. Phiel CJ, Klein PS (2001) Molecular targets of lithium action. Annu Rev Pharmacol Toxicol 41, 789-813.
52. David DC, Layfield R, Serpell L, Narain Y, Goedert M, Spillantini MG(2002) Proteasomal degradation of tau protein. J Neurochem 83, 176-185.
53. Freeman MP, Freeman SA (2006) Lithium: clinical considerations in internal medicine. Am J Med 119, 478-481.
54. SantaCruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, Forster C, Yue M, Orne J, Janus C, Mariash A, Kuskowski M, Hyman B, Hutton M, Ashe KH (2005) Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476-481.
55. Bhat RV, Haeberlein SLB, Avila J (2004) Glycogen synthase kinase 3: a drug target for CNS therapies. J Neurochem 89, 1313-1317.
56. Tariot PN, Aisen PS (2009) Can lithium or valproate untie tangles in Alzheimer's disease? J Clin Psychiatry 70, 919-921.
57. Srisurapanont M, Pratoomsri W, Maneeton N (2000) Evaluation of three simple methods for predicting therapeutic lithium doses. Psychiatry Res 94, 83-88.
58. Tsaltas E, Kontis D, Boulougouris V, Papadimitriou GN (2009) Lithium and cognitive enhancement: leave it or take it? Psychopharmacol (Berl) 202, 457-476.
59. Macdonald A, Briggs K, Poppe M, Higgins A, Velayudhan L, Lovestone S (2008) A feasibility and tolerability study of lithium in Alzheimer's disease. Int J Geriatr Psychiatry 23, 704-711.
60. Hampel H, Ewers M, Burger K, Annas P, Mortberg A, Bogstedt A, Frolich L, Schroder J, Schonknecht P, Riepe MW, Kraft I, Gasser T, Leyhe T, Moller HJ, Kurz A, Basun H (2009) Lithium trial in Alzheimer's disease: a randomized, singleblind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry 70, 922-931.
61. Pomara N (2009) Lithium treatment in Alzheimer's disease does not promote cognitive enhancement, but may exert longterm neuroprotective effects. Psychopharmacol (Berl) 205, 169-170.